Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.

Navigating Cost Management: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and ImmunityBio, Inc. over the past decade. Viatris Inc., a global healthcare giant, has consistently maintained higher SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a staggering 210% increase from 2014. In contrast, ImmunityBio, Inc., a burgeoning biotech firm, saw its SG&A expenses rise by nearly 2,900% over the same period, reaching around $130 million in 2023. This stark contrast highlights the differing scales and growth trajectories of these companies. While Viatris focuses on maintaining its vast operations, ImmunityBio is investing heavily in its expansion. Understanding these trends offers valuable insights into strategic financial management within the pharmaceutical industry.